#clinical trial data | Explore Tumblr Posts and Blogs

distinguished-slacker · 2 years

Text

The real question is…when the hell did Kureto, Guren and Shinya get a PhD on science to understand scientific data and even carry their own experiments?

#cat16 is literally about a bunch of 16 year olds sharing confidential clinical trials data with each other and understanding it #HOW #it’s not even only about spellcraft but also genetics pharmacology etc.#or you can also take it as actual adult scientists letting a bunch of teenagers carry their investigation #owari no seraph #seraph of the end #ichinose guren catastrophe at 16 #catastrophe at 16

86 notes · View notes

dermatology-cro · 23 days

Text

#future of clinical research #future of clinical research industry #future of clinical trials #future of clinical data management #recent advances in clinical trials impact factor

0 notes

octalsoft · 29 days

Text

Does Your Electronic Data Capture (EDC) System Provide Enough Flexibility

According to the Tufts Centre for the Study of Drug Development (Tufts CSDD) study, at least one protocol change happens in more than half of all clinical trials. These changes have the potential to destabilize locations and research teams, causing inefficiencies. For example, if a change affects how therapy is administered or how and what data is collected, sites may need to re-consent with a patient. Changes in research procedures cause big logistical issues for everyone involved and waste a lot of time, especially when it comes to clinical trial data gathering.

Modern EDC Systems Must Accommodate Protocol Amendments

Data collection and patient visit schedules are disrupted if a protocol amendment necessitates. According to the Tufts CSDD research, clinical trials average 2.2 to 2.3 protocol revisions. This means that electronic data capture in clinical trials may have to be shut down several times, which is both disruptive and wasteful. Given the frequency with which changes occur, EDC systems should be built to sustain regular operations while adapting to changes.

Amendments that codify clinical trial data gathering, on the other hand, must be explicitly indicated for users to ensure that each modification is implemented throughout the study. If a new field is introduced to a form, the user interface should make it apparent that the new field must be filled out. Otherwise, clinical research coordinators may overlook the addition of a new item to their process. These sorts of notifications are straightforward but useful procedures that should be common in EDC systems. A clear approach for training or retraining users on any new feature should be included as part of that infrastructure.

Adaptable Designs, Adaptable EDC

Clinical trial design is becoming increasingly difficult. Adaptive trials, for example, evolve over time, which means that an EDC system must account for every conceivable path the trial may take. There are also several types of trials, such as basket, umbrella, and platform, each of which need a versatile electronic data capture software for clinical trials. As sponsors employ a broader range of complicated clinical trial designs, their EDC systems must be capable of implementing complex changes—often in the middle of a study.

Telehealth consultations quickly became a viable and essential alternative to in-person sessions during the COVID-19 epidemic. Remote visits in clinical trials increased in 2020 and 2021 as a result of site closures, travel limitations, and patients' reluctance to attend a medical center. Data from telemedicine platforms, wearables, sensors, and other sources must be integrated into EDC systems for this decentralized research. They also need the capability and flexibility to support numerous treatment arms as well as the mid-study adjustments that are inherent in adaptive trial designs.

Octalsoft EDC Supports the Next Era of Clinical Data Management

Octalsoft is constantly improving electronic data capture systems to match the flexibility demands of current clinical trials. EDC does not need any downtime for protocol changes. Following implementation, site users are automatically allocated the tasks necessary to accommodate the change, and revised eCRF completion criteria may be published and made instantly accessible, informing site users about the eCRF modifications and what new/changed data are required. Once a modification is made, it may be implemented without disrupting patient site appointments or bringing the entire system down. The ultimate goal: consistent, uninterrupted performance.

For reporting reasons, effective electronic data capture solutions log all modifications so users know when and how they were applied. modifies can also be reversed if, for example, a patient withdraws consent following a protocol modification that modifies what data they must supply. EDC saves users time by automating as many of these procedures as possible, allowing them to focus more on patients and the day-to-day operations of clinical trials.

Although all aspects of a clinical trial are rigorously monitored, studies are becoming increasingly complicated, protocol changes are regular, and recruitment is unpredictable. Furthermore, our environment is continually and rapidly changing, which has a direct influence on both trials and participants.

There are three core reasons why Octalsoft EDC is a firm favorite for clinical data management, clinical operations, and clinical database programming teams:

1. High Configurability

The majority of EDC studies may be built without the use of special functions. A study's components may be customized in 95% of cases. Octalsoft and our clients both have libraries of reusable custom functions to help them construct new studies faster. Customers can employ EDC's Professional Services team or create their own sophisticated research. Other solutions may need the development of additional functionality by a vendor in order to support a certain protocol.

2. Flexibility

EDC enables the ability to personalize the study construct and execute any protocol amendment or other mid-study design modification to provide support for any protocol, including complex adaptive designs and master protocols.

3. Transformational Study Build Processes

Octalsoft is dedicated to streamlining operations while maintaining quality and efficacy. By allowing greater study-build customization through the user interface, our next-generation study design technology changes the process. This novel method incorporates complicated casebook dynamic behavior. Because clinical data capture is no longer limited to EDC, we're centralizing the definition of a study across applications, including developing data source agnostic edit checks and data definitions (i.e., the same data definitions and edit checks would apply whether collected via EDC or eCOA).

Many of the edit checks we write now (to account for all eventualities) never run. A recent study at a big pharma customer revealed that anywhere from 45% to 75% of scheduled edit checks were never completed.

Octalsoft is enabling a more intelligent, risk-based approach to building research. As part of our next-generation data platform that supports the progression of clinical data management to clinical data science, we maintain data quality by concentrating edit check development on the most prevalent cases and employing AI/ML to detect data abnormalities. As a result, the amount of custom programming necessary to implement research will be reduced.

These three fundamental elements result in simplified study builds, which speed up the study construction procedure for many clinical studies.

Conclusion

To meet the clinical trial landscape's complexity and unpredictability, the only logical technology solution is a system with the functionality, adaptability, and flexibility to properly fit with your research. This necessitates the use of a system that is adaptable, can use pre-existing custom functions, and can create new custom functions to meet specific needs. If your EDC lacks them, it will be unable to expand and accommodate the rising number of complex/innovative trials.

This adaptability is one of the primary reasons Octalsoft's EDC has been chosen by over 30,000 users.

Octalsoft's staff collaborates with you to understand your study objectives, study design, and any special requirements. Alternatively, our training experts will assist you in creating your own studies.

Want to know more about how Octalsoft can help boost the flexibility and modularity of your next clinical trial? Book a demo with us today.

#data capture software #edc software #electronic data capture #edc clinical trials #electronic data capture software #edc system #edc in clinical research

0 notes

hectorresearch · 29 days

Text

#clinicalresearch #clinical data management #clinical trials #health #clinical #site management organization #clinical trial management organization

1 note · View note

chemxpert · 1 month

Text

Essence of Drug Master Files (DMF) in Pharmaceutical Industry

In the vast realm of pharmaceuticals, ensuring safety, efficacy, and compliance is paramount. Among the many regulatory requirements, the drug master file (DMF) stands as a cornerstone for facilitating the smooth approval process of pharmaceutical products. This comprehensive guide delves into the intricacies of DMFs, exploring their significance, types, and relevance in the pharmaceutical landscape.

#new rules for clinical trials in India #top 10 pharmaceutical companies #biggest pharmaceutical companies #types of data in pharmaceutical industry #pharmaceutical company datasets #pharmaceutical product development

1 note · View note

marketresercher · 2 months

Text

Clinical Trial Management System (CTMS) Market Share, Size 2024 Movements by Analysis, Progression Status, Revenue Expectation to 2030

****Everything You Need to Know About Clinical Trial Management System (CTMS) everything is Here....!

The Comprehensive study on Clinical Trial Management System (CTMS) Market includes historical data as well as share, size, and projection information for the major players, geographies, applications, and product categories for the years 2024 to 2030. The Market study includes comprehensive insights on the competitive environment, description, broad product portfolio of key players, SWOT analysis, and significant business strategy implemented by rivals, revenue, Porters Five Forces Analysis, and sales projections. The report also features an impact analysis of the market dynamics, highlighting the factors currently driving and limiting market growth, and the impact they could have on the short, medium, and long-term outlook. The main goal of the paper is to further illustrate how the latest scenario, the economic slowdown, and war events affect the market for Clinical Trial Management System (CTMS).

Clinical Trial Management System (CTMS) Market is growing at a +14.7% CAGR during the forecast period 2024-2030. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

The Top Key Players profiled in the report:

Oracle, Medidata Solutions, Parexel International Corporation, IBM, Bioclinica, Bio-Optronics, Datatrak International, Veeva Systems, Mastercontrol, DSG, ERT, Advarra Technology Solutions, Mednet Solutions, Arisglobal, DZS Clinical Services (WDB Holdings Co. Ltd) and others.

Click the link to get a free sample copy of the report :

(*If you have any special requirements, please let us know and we will provide you with the report as you wish.)

Clinical Trial Management System (CTMS) Market Segmentation:

Clinical Trial Management System Market by Product, 2020-2029, (USD Million)

Software

Services

Clinical Trial Management System Market by Delivery, 2020-2029, (USD Million)

Web-Based (On-Demand)

Licensed Enterprise (On-Premises)

Cloud-Based (SAAS)

Clinical Trial Management System Market by Deployment, 2020-2029, (USD Million)

Enterprise-Wide CTMS

On-Site CTMS

Clinical Trial Management System Market by End User, 2020-2029, (USD Million)

Large Pharma-Biotech Companies

CROS

Medical Device Manufacturers

Small & Mid-Sized Pharma-Biotech Companies

Other End Users

Based on geography, the global market for Clinical Trial Management System (CTMS) and Disruptions has been segmented as follows:

North America (United States, Canada, Mexico)

South America (Brazil, Argentina, Ecuador, Chile)

Asia Pacific (China, Japan, India, Korea)

Europe (Germany, UK, France, Italy)

Middle East Africa (Egypt, Turkey, Saudi Arabia, Iran) and more.

Strategic Points Covered in Clinical Trial Management System (CTMS) Market Directory:

To study and analyze the global market size (value & volume) by company, key regions/countries, products and application, history data, and forecast to 2030.

To understand the structure of market by identifying its various sub segments.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

Focuses on the key global manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the growth trends, future prospects, and their contribution to the total market.

To project the value and volume of submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Clinical Trial Management System (CTMS)

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the Clinical Trial Management System (CTMS) market strategies, geographic and business segments of the leading players in the market.

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Clinical Trial Management System (CTMS)

Take a look at the full report with detailed TOC here:

Some of the key questions scrutinized in the study are:

Which companies are expanding litanies of products with the aim to diversify product portfolio?

Which companies have drifted away from their core competencies and how have those impacted the strategic landscape of the Clinical Trial Management System (CTMS) market?

Which companies have expanded their horizons by engaging in long-term societal considerations?

Which firms have bucked the pandemic trend and what frameworks they adopted to stay resilient?

What are the marketing programs for some of the recent product launches?

We offer customization on the Clinical Trial Management System (CTMS) market report based on specific client requirements:

20% free customization.

Five Countries can be added as per your choice.

Five Companies can add as per your choice.

Free customization for up to 40 hours.

After-sales support for 1 year from the date of delivery.

Get More: https://exactitudeconsultancy.com/primary-research/

Thank you for your interest in the Clinical Trial Management System (CTMS) Market research publications; you can also get individual chapters or regional/country report versions such as Germany, France, China, Latin America, GCC, North America, Europe or Asia……

About Us:

Exactitude Consultancy is a Market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our professional team works hard to fetch the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you. So, whether it is the latest report from the researchers or a custom requirement, our team is here to help you in the best possible way.

Contact: Exactitude Consultancy PHONE NUMBER +1(704) 266-3234

EMAIL ADDRESS: [email protected]

0 notes

market-insider · 3 months

Text

Clinical Trials : Holistic Exploration of the Current State and Future Outlook

The global clinical trials market size is expected to reach USD 123.5 billion by 2030, expanding at a CAGR of 6.49 from 2024 to 2030, according to a new report by Grand View Research, Inc. An increase in the volume and complexity of clinical trials has been witnessed lately, which plays an important role in the R&D of new drugs and products. The market witnessed a decline of 6% in 2020 owing to the COVID-19 pandemic. However, the market is projected to recover from 2021 onwards. In addition, clinical trials have become increasingly costly, adding to the overall cost of developing a drug.

Clinical Trials Market Report Highlights

The phase III clinical trials segment dominated the market with a 53.3% share in 2023. This can be attributed to the complexity of this phase

The interventional studies segment dominated the market in 2023. It is one of the most prominent methods used in clinical trials in the study design segment owing to the increasing demand for the intervention for clinical trials by researchers

North America held 50.3% of the market share in 2023. Favorable government initiatives and the presence of a large number of players in the U.S. that offer advanced services are responsible for market growth

Asia Pacific region is anticipated to grow at the fastest CAGR over the forecast period owing to the increasing patient pool and cost-efficient services.

For More Details or Sample Copy please visit link @: Clinical Trials Market Report

The increasing need for developing new drugs for chronic diseases, such as cancer, respiratory disorders, diabetes, cardiovascular diseases, and others, is creating immense pressure on the healthcare industry. The COVID-19 pandemic and the increasing demand for developing a suitable treatment are driving the market. The high number of people affected by the disease further depicts an increasing need for therapeutics & vaccines. Currently, there are 288 therapeutics and 106 vaccines under development, out of which, nearly 7.0% of therapeutics are in Phase IV, 21.0% in Phase III, and 43.0% & 13.0% in Phase II & Phase I, respectively.

The pandemic has resulted in the global disruption of traditional onsite clinical trials. Hence, regulatory bodies worldwide have undertaken various initiatives for fast-tracking clinical trials for the development of innovative solutions. One such instance is Solidarity, an international clinical trial launched by the WHO to find effective treatment against COVID-19. Although the pandemic has forced many medical device & drug developers to revise the approach to such crises, integrating best practices within clinical trial procedures & adapting to virtual trials, which can support the continuous development of therapeutics.

ClinicalTrials #HealthcareResearch #MedicalInnovation #DrugDevelopment #PatientRecruitment #Biopharmaceuticals #ClinicalResearch #RegulatoryCompliance #DataManagement #PatientEngagement #PrecisionMedicine #TherapeuticTrials #CROs #ClinicalResearchOrganizations #GlobalHealth #ClinicalStudyDesign #PharmaceuticalIndustry #BiotechResearch #ClinicalEndpoints #HealthTechIntegration

0 notes

neosciencehub · 3 months

Text

Neuralink's Human Trials: Regulatory Hurdles of Neurotechnology

Neuralink's Human Trials: Regulatory Hurdles of Neurotechnology @neosciencehub #neosciencehub #science #neuralink #humantrails #neurotechnology #elonmusk #FDA #healthcare #medicalscience #ClinicalResearch #health #AITech #BrainComputer #DataPrivacy #NSH

The journey of Neuralink, Elon Musk’s ambitious neurotechnology venture, to its first human trials represents a significant achievement in the field of biomedical innovation. However, this path was not without its challenges. Neo Science Hub’s Scientific Advisory Team examines the intricate regulatory landscape that companies like Neuralink must navigate, highlighting the complex interplay of…

View On WordPress

#Biomedical Ethics #Brain-Computer Interface #Clinical Trials #Data Security #Elon Musk #Ethical Technology #FDA Approval #featured #Health Law #Medical Innovation #Neuralink #Neuroscientific Research #Neurotechnology Regulation #Patient Safety #Regulatory Compliance #sciencenews #Technological Advancements

0 notes

pharmaceuticaltech · 4 months

Text

#Clinical Trials #Clinical Trial Management #Efficient Data Management

0 notes

omkarpatel · 5 months

Text

The Clinical Mass Spectrometry Market is a rapidly growing market owing to increasing applications of mass spectrometry in clinical research and diagnostics

Clinical mass spectrometry finds wide application in clinical research and drug development for disease diagnosis, monitoring disease progression, drug metabolism studies etc. It helps in detection of trace level molecules present in biological samples like blood, urine etc. and provides accurate molecular weight information. The ability of mass spectrometers to perform multitask functions like identification, quantification and structural characterization has increased its demand in clinical settings. The Clinical Mass Spectrometry Market is estimated to be valued at US$ 6.37 Bn in 2023 and is expected to exhibit a CAGR of 26% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market key trends: One of the key trends propelling the growth of clinical mass spectrometry market is increasing adoption of LC-MS/MS systems for newborn screening. Newborn screening involves screening of all newborns for certain genetic, endocrine and metabolic disorders which if left untreated can lead to serious health issues or death. Mass spectrometry based newborn screening allows diagnosis of over 50 different disorders in a single sample analysis. Growing incidences of chronic and genetic diseases is driving the adoption of mass spectrometry for newborn screening procedures globally. Additionally, technological advancements improving resolution, throughput and ease of use of mass spectrometers is supporting their increased adoption in clinical research and disease diagnosis. Porter’s Analysis Threat of new entrants: New companies find it difficult to enter into the market as it requires heavy capital investments for R&D, manufacturing and distribution networks. They also face strong competition from existing key players. Bargaining power of buyers: Buyers have moderate bargaining power as there are many established players providing similar clinical mass spectrometry devices. However, highly differentiated products increase switching costs for buyers. Bargaining power of suppliers: Suppliers have low to moderate bargaining power as key components can be substituted and players have multiple sourcing options to avoid dependence on single/few suppliers. Threat of new substitutes: Threat of new substitutes is low as mass spectrometry technology provides unique capabilities for complex proteomic and metabolomic analysis that are difficult to substitute. Competitive rivalry: Intense as key players compete on performance, pricing and aftersales support. SWOT Analysis Strength: Advanced technologies enabling high throughput screening and accurate detection of biomarkers. Wide applications in R&D, clinical diagnosis and treatment monitoring. Weakness: High installation and maintenance costs limiting adoption in low resource settings. Require highly skilled workforce for operation. Opportunity: Growing proteomic and metabolomic research driving demand. Rising incidence of cancers and other chronic diseases creating avenues. Threats: Stringent regulatory approvals delaying new product launches. Economic slowdowns impacting research spending of pharma companies. Key players operating in the clinical mass spectrometry market are SCIEX AB(US), Thermo Fisher Scientific (US), Agilent Technologies (US), Waters Corporation (US), PerkinElmer Inc. (US), Shimadzu Corporation (Japan), Bruker Corporation (US), Analytik Jena (Germany), JEOL Ltd. (Japan), Hiden Analytical (UK), and MKS Instruments (US), among others. Major players are focusing on new product development and geographical expansion to consolidate their market shares.

#medical devices #clinical trials #data analysis #research scientist

0 notes

dermatology-cro · 1 month

Text

#clinical trial photography #data in clinical trials #what is clinical photography #clinical photo

0 notes

octalsoft · 2 months

Text

Best Electronic Data Capture (EDC) Software in 2024: Why Octalsoft Stands Out

In today's rapidly evolving clinical research landscape, efficient and secure data capture is paramount. Electronic Data Capture (EDC) software has become the backbone of clinical trials, streamlining data collection, management, and analysis. According to a 2024 report by Statista, while the share of office-based U.S. doctors using such systems was around 18 percent in 2001, the uptake stood at some 88 percent in 2021. By 2027, the market value of EHRs is forecasted to reach 47.2 billion U.S. dollars, up from 29 billion U.S. dollars in 2020.

However, with so many alternatives available, you may find deciding on the best EDC difficult. This article digs at outlining the strengths of Octalsoft's EDC system and demonstrating its edge over other options.

Understanding EDC Software:

EDC software acts as a digital repository for clinical trial data, enabling researchers to collect, manage, and analyze data electronically. It facilitates the creation of electronic Case Report Forms (eCRFs), which replace paper forms, promoting data accuracy and reducing errors. Additionally, EDC software offers features like automated data validation, real-time data monitoring, and robust reporting functionalities. EDC systems have diverse functionalities, which result in their user base being quite extensive. From sponsors to CROS and on to sites, EDC systems are leveraged across functions to streamline modern clinical trial data collection, management, and data-backed strategy formulation.

Based on End-users, the electronic data capture systems market is segmented into CROs, Pharmaceutical & Biotechnology Firms, Hospitals/Healthcare providers, Medical Device Firms, and Others.

Key Considerations When Choosing EDC Software:

As you can gauge from the report above, it is clear that an EDC system is now a must-have for every clinical trial, regardless of who the end user is. But not every EDC system in the market is capable of handling the requirements of a modern-day clinical trial and therefore you must choose a system with caution and due diligence. Several factors come into play when selecting the best EDC software for your clinical research needs. Here are some crucial aspects to consider:

Scalability and Flexibility: The software should adapt to your study's size and complexity, accommodating diverse research needs.

Compliance and Security: Ensure the software adheres to regulatory requirements like HIPAA and GCP, guaranteeing data integrity and participant privacy.

User-Friendliness and Customization: The platform should be easy for researchers and participants to navigate, offering customization options to fit specific study requirements.

Integration Capabilities: Seamless integration with existing clinical trial management systems (CTMS) and other relevant software is crucial for efficient data transfer and analysis.

Cost and Value: While budget plays a role, consider the long-term value proposition offered by the software. Look beyond the initial cost and evaluate the return on investment (ROI) in terms of time savings, improved data quality, and overall research efficiency.

Why Octalsoft's EDC Stands Out:

With a deep understanding of the current clinical research landscape and a commitment to innovation, Octalsoft's EDC emerges as a leading contender in the market. Here's what sets it apart:

1. Unmatched Scalability and Flexibility:

Octalsoft's EDC is architected to adapt to any study size and complexity. Whether you're conducting a small, single-site trial or a large, multi-national study, the platform effortlessly scales to your needs. Its flexible design allows for the creation of customized eCRFs, catering to diverse clinical trial requirements.

2. Unwavering Commitment to Compliance and Security:

Octalsoft prioritizes data integrity and participant privacy. The platform adheres to the strictest regulatory guidelines, including HIPAA, GCP, and GDPR, ensuring data security and compliance throughout the research process. Robust security features like role-based access control, audit trails, and encryption provide an additional layer of protection.

3. Intuitive User Interface and Streamlined Workflow:

Octalsoft's user-centric design philosophy translates into an intuitive and user-friendly interface. Both researchers and participants can navigate the platform easily, maximizing user adoption and minimizing training needs. The system incorporates pre-built templates and functionalities to streamline data collection and workflow, saving researchers valuable time and resources.

4. Seamless Integration and Interoperability:

Octalsoft's EDC seamlessly integrates with leading CTMS solutions and other relevant software. This fosters efficient data exchange and eliminates the need for manual data entry, minimizing errors and streamlining data analysis processes.

5. Competitive Cost and Proven Value:

Octalsoft offers competitive pricing models, making its EDC solution accessible to a wide range of research organizations. Additionally, the platform's features and functionalities deliver significant value, translating into tangible benefits such as:

Enhanced data accuracy and reduced errors

Streamlined data collection and management processes

Improved data visibility and real-time monitoring capabilities

Reduced regulatory burden and faster trial completion timelines

Beyond the Features: Octalsoft's Commitment to User Success:

6. Capable of including Amendments with zero downtime

Existing EDC software systems are frequently cited as a source of customer dissatisfaction, given the frequency with which they crash anytime there is a change. The contemporary and adaptable data structure of Octalsoft's EDC makes it possible for adjustments to be made with no downtime, removing the necessity to migrate data whenever an amendment is made and preventing end users from being kicked out of the system. This is more than just "no system downtime," it is in fact "no downtime for end users."

7. Maximizing Custom Functions

Every clinical trial is unique and hence requires an EDC that can adapt to the trial's specific requirements. Octalsoft’s EDC tool includes every functionality that a modern clinical trial could possibly need inclusive of a could-native platform and customization opportunities so that your EDC scales in tandem with your objectives.

8. Intuitive and Effective Study Builds

Building out intuitive and effective studies is yet another essential component of efficient EDC tools. The integrated environment of Octalsoft’s EDC offers a simplified study builder functionality that allows users to do so in much shorter time frames without having to hand over control to development execs to convert protocols to code.

9. Enhanced UX

Octalsoft’s EDC user interface is designed to be both modern as well as deeply intuitive so that the user can navigate the system easily without spending hours in training sessions. There are many additional functionalities within our EDC system that make for a stellar UX.

10. Quicker Access to Data

Octalsoft’s EDC offer a quick and clear overview of patient data at all times. With robust data validation checks and automatic calculations, Octalsoft’s EDC allows users to generate compliant, near submission-ready data; thus, facilitating faster submission of study results for regulatory approval.

11. Compliance and Standardization

Octalsoft’s EDC is compliant with regulatory requirements like 21 CFR Part 11 and HIPAA Privacy Act. It also offers users the ability to maintain a complete audit trail of clinical trial data generated. With Octalsoft’s EDC users can protect the confidentiality of subjects while adhering to independent industry standards like CDISC.

Conclusion:

Better features lead to an enhanced user experience and better UX leads to enhanced productivity and efficiency. This in turn results in better data and thus a better study. But our spirit of consistent innovation doesn’t stop with our EDC. As a core component of our eClinical suite Octalsoft's EDC is simply the starting point for revolutionizing clinical data management.

Choosing the appropriate EDC software is critical to the success of your clinical research projects. While the market has various solutions, Octalsoft's EDC stands out due to its unparalleled scalability, steadfast dedication to compliance, user-centric design, easy integration possibilities, and reasonable price. Its comprehensive features and dedicated user assistance make a compelling value proposition, making it the chosen choice for researchers looking to optimize clinical trials and fulfill their research objectives more successfully. As the healthcare industry continues to embrace digital transformation, EDC stands out as a cost-effective solution that enhances data quality, streamlines processes, and ultimately contributes to more successful clinical trials. But not every EDC can match the requirements of a modern clinical trial. Introducing Octalsoft’s EDC solution, your one-stop shop for all your data capture software needs. Interested in knowing how Octalsoft’s EDC can streamline your clinical trial data and ensure 10X accuracy? Book a Demo with us today.

#data capture software #edc software #edc clinical trials #electronic data capture software #edc system

0 notes

clinical-trial-solutions · 8 months

Text

eSource Solutions Provider | Clinical ink

Clinical ink eSource ecosystem is at the core of their clinical trial solutions, with the goal of integrating all incoming data into a uniform data platform that enables analytics inside & between studies. Their eSource solutions increase efficiency & reduce the cost of clinical trials, especially in complicated therapeutic areas. Contact them now!

#clinical trial management system #clinical trial recruitment #clinical trial data management #clinical research solutions #data management in clinical research #healthcare #technology

0 notes

howdoesone · 9 months

Text

How does one evaluate the need for booster shots for certain vaccines?

Vaccines have been a cornerstone in preventing infectious diseases and improving public health. While vaccines provide immunity against specific diseases, the need for booster shots arises in certain cases to enhance and sustain protection over time. Booster shots are additional doses of a vaccine given after the primary vaccination series to reinforce the immune response and provide long-term…

View On WordPress

#antibody levels #booster shots #breakthrough infections #clinical trials #emerging variants #epidemiological data #evolving pathogens #expert recommendations #outbreaks #real-world effectiveness data #regulatory authorities #serological testing #vaccine durability #vaccine immunity #vaccine-preventable diseases #waning immunity

0 notes

innonurse · 10 months

Text

What impact will the AI Bill of Rights have on US healthcare?

- By InnoNurse Staff -

The White House Blueprint for an AI Bill of Rights offers guidance on ethical and health equity concerns in healthcare as the sector seeks to eliminate repetitious chores and increase clinical efficiency with AI